Log in

NASDAQ:AEGR - Aegerion Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$1.97
0.00 (0.00 %)
(As of 12/7/2016)
Add
Today's Range
$1.97
Now: $1.97
$1.97
50-Day Range
$1.97
MA: $1.97
$1.97
52-Week Range
$1.23
Now: $1.97
$10.85
VolumeN/A
Average Volume635,262 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:AEGR
CUSIP00767E10
Phone+1-617-5007867

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive AEGR News and Ratings via Email

Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter.


Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions

What is Aegerion Pharmaceuticals' stock symbol?

Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."

How were Aegerion Pharmaceuticals' earnings last quarter?

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $43 million. Aegerion Pharmaceuticals's revenue was down 39.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.55) EPS. View Aegerion Pharmaceuticals' Earnings History.

Has Aegerion Pharmaceuticals been receiving favorable news coverage?

News headlines about AEGR stock have been trending extremely negative on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aegerion Pharmaceuticals earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Aegerion Pharmaceuticals.

Who are some of Aegerion Pharmaceuticals' key competitors?

What other stocks do shareholders of Aegerion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aegerion Pharmaceuticals investors own include Allergan (AGN), BioMarin Pharmaceutical (BMRN), Netflix (NFLX), Tesla (TSLA), Ariad Pharmaceuticals (ARIA), Arrowhead Pharmaceuticals (ARWR), Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT) and Keryx Biopharmaceuticals (KERX).

What is Aegerion Pharmaceuticals' stock price today?

One share of AEGR stock can currently be purchased for approximately $1.97.

What is Aegerion Pharmaceuticals' official website?

The official website for Aegerion Pharmaceuticals is http://www.aegerion.com/.

How can I contact Aegerion Pharmaceuticals?

Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.


MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  703
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel